Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarin Official Calls Drisapersen AdCom ‘Critical Thinking On Display’

Executive Summary

CMO says advisory committee was tough on proposed Duchenne muscular dystrophy treatment in part because it was first to reach that stage.

You may also be interested in...



Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups

Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.

Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too

The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.

US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward

System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS057338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel